title: Mutant IDH1 is an effective immunotherapeutic target for glioma.
abstract: A neoantigen derived from mutant IDH1 can promote antitumor CD4(+) T-cell and antibody responses.
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D005910:Glioma / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics* / Q000276:immunology*; D008297:Male; D050505:Mutant Proteins / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D050505:Mutant Proteins; D007521:Isocitrate Dehydrogenase